November, is a month dedicated to raising awareness and support efforts to educate people about stomach cancer, including risk factors, prevention and early detection. Established in 2010, Stomach Cancer Month currently aims to support the 1 out of 111 people that are diagnosed with Stomach Cancer.1
About Stomach Cancer
Stomach cancer, also known as gastric cancer, is the accumulation of an abnormal (malignant, cancerous) group of cells that form a mass in a part of the stomach.
Around 90-95 percent of all stomach cancers are a type referred to as adenocarcinoma of the stomach. In this version, the cancer develops from the cells that form the mucosa, the most superficial lining of the stomach that produces mucus.
Symptoms and Risk Factors
Though gastric cancer can be difficult to recognise initially, there are several early symptoms that have developed in some patients. These are:
- A sensation of being very full during meals
- Vomiting (may contain blood)
- Indigestion that does not go away
Furthermore, there are risk factors that have been linked to stomach cancer, these include:
- Smoking – long-term smokers have twice the risk of developing stomach cancer compared to non-smokers
- Family History – having a close relative who has/had stomach cancer
- Diet – people who regularly eat salted fish, salty foods, smoked meats and pickled vegetables
- Age – the risk of developing stomach cancer increases significantly after the age of 55.2
It is important that if you notice any of the symptoms related to stomach cancer that you visit your GP immediately.
Randox Biosciences Product Offerings
We currently offer a GastroPanel Array, which is a multiplex test engineered to diagnose those at risk of developing peptic ulcers and gastric cancer using non-invasive methods.
Our GastroPanel Array encompasses two quantitative assays, a H. pylori assay for the detection of antibodies produced in response to a H. pylori infection, a common cause of gastric cancer as well as a 3plex GastroPanel assay, for the detection of pepsinogen I (PGI), pepsinogen II (PGII) and gastrin 17 (G17).
Currently recorded as the world’s 5th most common cancer, the majority of gastric cancer cases are diagnosed after presenting as an emergency, when treatment may be less effective due to the cancer being at an advanced stage, highlighting the need for the availability of diagnostics tests such as our Gastropanel Array which enables practitioners to administer prompt treatment and ultimately increase survival rates on a global scale.
There are many other key benefits of using Randox Biosciences Gastropanel Array, which are:
- A single blood sample can provide a comprehensive patient profile of gastric health
- Accurate and precise results every time
- Easy to use multiplex tests reducing costs and labour time
- Improving patient care through less invasive testing
To find out more email us at email@example.com
1 – No Stomach for Cancer
2 – Medical News Today
*for research use only